Skip to main content

 

Rheumatic Patients Are at Risk for COVID Death

MedPage Today

Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease (RMD) patients, based on the efforts of the North American Task force.

RheumNow Podcast – Rheumatology Burnout (1.29.2021)

Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com.

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to review on this week's podcast.

Hydroxychloroquine Shortage During COVID-19

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, and inflammatory bowel disease, have an augmented risk of cardiovascular (CV) outcomes with

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

EULAR Guidance on Patient Adherence to Meds

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force

Plaquenil Does Not Protect Lupus Patients from COVID-19 (Best of 2020)

Editor's note: This article originally appeared May 14, 2020, and is being shared again as part of RheumNow's "Best of 2020".

Update on Polymyalgia Rheumatica and Giant Cell Arteritis (Best of 2020)

Editor's note: This article originally appeared August 24, 2020, and is being shared again as part of RheumNow's "Best of 2020".

Social

Follow us on LinkedIn too! https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Dr. John Cush @RheumNow ( View Tweet )
3 years ago
Impressive free read and review of Neutrophils and Netosis in Autoimmune and Autoinflammatory disorders (Nature Reviews) from Kapland & Wigerblad at the NIH. https://t.co/w4cIwcQMkt https://t.co/ReA9xM2X4j
Dr. John Cush @RheumNow ( View Tweet )
3 years ago
Are we giving enough HCQ?🤔 Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48) #ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
3 years 1 month ago
#ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
#ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22. https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB
Dr. John Cush @RheumNow ( View Tweet )
3 years 1 month ago
Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7
Richard Conway @RichardPAConway ( View Tweet )
3 years 1 month ago
13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive crit -Don't count other cause Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology Lab: +LA, aCL/B2GP IgM/IgG/titer Total: 3+ clin, 3+ lab @RheumNow https://t.co/YeKW0orjZC
3 years 1 month ago
Plenary: Tyrosine kinase 2 (TYK2) ◦ Mediates signaling of Type I IFNs, IL-23, and IL-12 ◦ Key cytokines involved in lupus pathogenesis ◦ Deucravacitinib oral TYK2 inhibitor ◦ Phase 2 RCT in SLE showed efficacy Pike M Abs1117 https://t.co/eJhNsM02Vl #ACR22 @RheumNow https://t.co/C6JQqR1DLj
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 1 month ago
Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful. @RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
Julian Segan @JulianSegan ( View Tweet )
3 years 1 month ago
×